Literature DB >> 27326125

A higher colour grade yellow plaque was detected at one year after implantation of an everolimus-eluting stent than after a zotarolimus-eluting stent.

Koshi Matsuo1, Yasunori Ueda1, Mayu Nishio1, Akio Hirata1, Mitsutoshi Asai1, Takayoshi Nemoto1, Ayaka Murakami1, Kazunori Kashiwase1, Kazuhisa Kodama1.   

Abstract

OBJECTIVE: Neoatherosclerosis or atherosclerosis progression is one of the mechanisms of long-term stent failure. Yellow plaque detected by angioscopy has been associated with advanced atherosclerosis and the future risk of a coronary event. We compared the yellow colour of the stented segment between zotarolimus-eluting stents (ZES) and everolimus-eluting stents (EES) at 1 year after implantation.
DESIGN: Cross-sectional study. PATIENTS: Consecutive patients underwent angioscopic examination 1 year after the implantation of ZES (n=45) or EES (n=45) at a de novo native coronary lesion. MAIN OUTCOME MEASURES: The maximum yellow colour grade (grade 0-3) of the stented segment, maximum and minimum neointima coverage grade (grade 0-2) and the presence of thrombus were examined. The neointima heterogeneity index was calculated as maximum - minimum coverage grade.
RESULTS: Maximum yellow colour grade was higher in EES than in ZES (1.3±0.9 vs 0.4±0.8, p<0.001) and maximum (2.0±0.2 vs 1.2±0.5, p<0.001) and minimum (1.5±0.6 vs 0.7±0.5, p<0.001) coverage grade was higher in ZES than in EES. The neointima heterogeneity index was not different between ZES and EES (0.4±0.5 vs 0.5±0.6, p=0.42). The incidence of thrombus was very low and was not different between ZES and EES (2% vs 4%, p=0.55).
CONCLUSIONS: Although both ZES and EES had good healing with homogeneous neointima coverage and a low incidence of thrombus, EES had more advanced atherosclerosis as shown by the presence of higher grade yellow plaque than ZES at 1 year after implantation.

Entities:  

Year:  2013        PMID: 27326125      PMCID: PMC4832713          DOI: 10.1136/heartasia-2013-010378

Source DB:  PubMed          Journal:  Heart Asia        ISSN: 1759-1104


  31 in total

1.  One step forward and two steps back with drug-eluting-stents: from preventing restenosis to causing late thrombosis and nouveau atherosclerosis.

Authors:  Gaku Nakazawa; Marc Vorpahl; Aloke V Finn; Jagat Narula; Renu Virmani
Journal:  JACC Cardiovasc Imaging       Date:  2009-05

2.  Angioscopic comparison of neointimal coverage between zotarolimus- and sirolimus-eluting stents.

Authors:  Masaki Awata; Shinsuke Nanto; Masaaki Uematsu; Takakazu Morozumi; Tetsuya Watanabe; Toshinari Onishi; Osamu Iida; Fusako Sera; Jun-ichi Kotani; Masatsugu Hori; Seiki Nagata
Journal:  J Am Coll Cardiol       Date:  2008-08-26       Impact factor: 24.094

3.  Remodeling of in-stent neointima, which became thinner and transparent over 3 years: serial angiographic and angioscopic follow-up.

Authors:  M Asakura; Y Ueda; S Nanto; A Hirayama; T Adachi; M Kitakaze; M Hori; K Kodama
Journal:  Circulation       Date:  1998-05-26       Impact factor: 29.690

4.  High incidence of thrombus formation at 18 months after paclitaxel-eluting stent implantation: angioscopic comparison with sirolimus-eluting stent.

Authors:  Masahiko Hara; Masami Nishino; Masayuki Taniike; Nobuhiko Makino; Hiroyasu Kato; Yasuyuki Egami; Ryu Shutta; Hitoshi Yamaguchi; Jun Tanouchi; Yoshio Yamada
Journal:  Am Heart J       Date:  2010-05       Impact factor: 4.749

5.  The healing process of infarct-related plaques. Insights from 18 months of serial angioscopic follow-up.

Authors:  Y Ueda; M Asakura; O Yamaguchi; A Hirayama; M Hori; K Kodama
Journal:  J Am Coll Cardiol       Date:  2001-12       Impact factor: 24.094

6.  Histopathological findings of new in-stent lesions developed beyond five years.

Authors:  Katsuyuki Hasegawa; Hideo Tamai; Eisho Kyo; Kunihiko Kosuga; Shigeru Ikeguchi; Tatsuhiko Hata; Masaharu Okada; Shinya Fujita; Takafumi Tsuji; Shinsaku Takeda; Rei Fukuhara; Yuetsu Kikuta; Seiichiro Motohara; Kazuo Ono; Eiji Takeuchi
Journal:  Catheter Cardiovasc Interv       Date:  2006-10       Impact factor: 2.692

7.  Angioscopic assessment of arterial repair following biodegradable polymer-coated biolimus A9-eluting stent implantation. - Comparison with durable polymer-coated sirolimus-eluting stent-.

Authors:  Masaki Awata; Masaaki Uematsu; Fusako Sera; Takayuki Ishihara; Tetsuya Watanabe; Masashi Fujita; Toshinari Onishi; Osamu Iida; Yoshio Ishida; Shinsuke Nanto; Seiki Nagata
Journal:  Circ J       Date:  2011-03-05       Impact factor: 2.993

8.  Angioscopic evaluation of neointima coverage: sirolimus drug-eluting stent versus bare metal stent.

Authors:  Jota Oyabu; Yasunori Ueda; Nobuyuki Ogasawara; Katsuki Okada; Atsushi Hirayama; Kazuhisa Kodama
Journal:  Am Heart J       Date:  2006-12       Impact factor: 4.749

9.  Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis.

Authors:  David R Holmes; Martin B Leon; Jeffrey W Moses; Jeffrey J Popma; Donald Cutlip; Peter J Fitzgerald; Charles Brown; Tim Fischell; Shing Chiu Wong; Mark Midei; David Snead; Richard E Kuntz
Journal:  Circulation       Date:  2004-02-10       Impact factor: 29.690

10.  Lack of association between large angiographic late loss and low risk of in-stent thrombus: angioscopic comparison between paclitaxel- and sirolimus-eluting stents.

Authors:  Masamichi Takano; Masanori Yamamoto; Daisuke Murakami; Shigenobu Inami; Kentaro Okamatsu; Koji Seimiya; Takayoshi Ohba; Yoshihiko Seino; Kyoichi Mizuno
Journal:  Circ Cardiovasc Interv       Date:  2008-08       Impact factor: 6.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.